Citius Oncology, Inc. (CTOR) — Stock Valuation & Research

Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.

CTOR key statistics

Price$0.58
Market cap$53.94M
SectorHealthcare
IndustryMedical - Pharmaceuticals
ExchangeNASDAQ
52-week range0.491-1.83
Beta3.4

Explore CTOR's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.